399 related articles for article (PubMed ID: 20964457)
21. Ciclopirox for the treatment of superficial fungal infections: a review.
Gupta AK; Skinner AR
Int J Dermatol; 2003 Sep; 42 Suppl 1():3-9. PubMed ID: 12895181
[TBL] [Abstract][Full Text] [Related]
22. Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States.
Gupta AK; Joseph WS
J Am Podiatr Med Assoc; 2000; 90(10):495-501. PubMed ID: 11107710
[TBL] [Abstract][Full Text] [Related]
23. The use of topical therapies to treat onychomycosis.
Gupta AK; Ryder JE; Baran R
Dermatol Clin; 2003 Jul; 21(3):481-9. PubMed ID: 12956200
[TBL] [Abstract][Full Text] [Related]
24. Topical fenticonazole in dermatology and gynaecology: current role in therapy.
Veraldi S; Milani R
Drugs; 2008; 68(15):2183-94. PubMed ID: 18840006
[TBL] [Abstract][Full Text] [Related]
25. An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis.
Baran R; Tosti A; Hartmane I; Altmeyer P; Hercogova J; Koudelkova V; Ruzicka T; Combemale P; Mikazans I
J Eur Acad Dermatol Venereol; 2009 Jul; 23(7):773-81. PubMed ID: 19453778
[TBL] [Abstract][Full Text] [Related]
26. Ciclopirox nail lacquer topical solution 8%.
Gupta AK
Skin Therapy Lett; 2000; 6(1):1-5. PubMed ID: 11027420
[TBL] [Abstract][Full Text] [Related]
27. Comparative clinical evaluation of efficacy and safety of a formulation containing ciclopirox 8% in the form of a therapeutic nail lacquer in two different posologies for the treatment of onychomycosis of the toes.
Schalka S; Nunes S; Gomes Neto A
An Bras Dermatol; 2012; 87(1):19-25. PubMed ID: 22481647
[TBL] [Abstract][Full Text] [Related]
28. Ciclopirox nail lacquer for the treatment of onychomycosis: an open non-comparative study.
Shemer A; Nathansohn N; Trau H; Amichai B; Grunwald MH
J Dermatol; 2010 Feb; 37(2):137-9. PubMed ID: 20175847
[TBL] [Abstract][Full Text] [Related]
29. The low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatment.
Sugiura K; Sugimoto N; Hosaka S; Katafuchi-Nagashima M; Arakawa Y; Tatsumi Y; Jo Siu W; Pillai R
Antimicrob Agents Chemother; 2014 Jul; 58(7):3837-42. PubMed ID: 24752277
[TBL] [Abstract][Full Text] [Related]
30. An open randomized comparative study to test the efficacy and safety of oral terbinafine pulse as a monotherapy and in combination with topical ciclopirox olamine 8% or topical amorolfine hydrochloride 5% in the treatment of onychomycosis.
Jaiswal A; Sharma RP; Garg AP
Indian J Dermatol Venereol Leprol; 2007; 73(6):393-6. PubMed ID: 18032857
[TBL] [Abstract][Full Text] [Related]
31. Ciclopirox nail lacquer 8%: in vivo penetration into and through nails and in vitro effect on pig skin.
Ceschin-Roques CG; Hänel H; Pruja-Bougaret SM; Luc J; Vandermander J; Michel G
Skin Pharmacol; 1991; 4(2):89-94. PubMed ID: 1831626
[TBL] [Abstract][Full Text] [Related]
32. Ciclopirox (Loprox) gel for superficial fungal infections.
Gupta AK; Bluhm R
Skin Therapy Lett; 2004; 9(7):4-5, 9. PubMed ID: 15334276
[TBL] [Abstract][Full Text] [Related]
33. In vitro permeation and penetration of ciclopirox olamine from poloxamer 407-based formulations--comparison of isolated human stratum corneum, bovine hoof plates and keratin films.
Täuber A; Müller-Goymann CC
Int J Pharm; 2015 Jul; 489(1-2):73-82. PubMed ID: 25895717
[TBL] [Abstract][Full Text] [Related]
34. Congenital candidal onychomycoses: effective cure with ciclopirox olamine 8% nail lacquer.
Sardana K; Garg VK; Manchanda V; Rajpal M
Br J Dermatol; 2006 Mar; 154(3):573-5. PubMed ID: 16445808
[No Abstract] [Full Text] [Related]
35. Visualisation of penetration of topical antifungal drug substances through mycosis-infected nails by matrix-assisted laser desorption ionisation mass spectrometry imaging.
Endringer Pinto F; Bagger C; Kunze G; Joly-Tonetti N; Thénot JP; Osman-Ponchet H; Janfelt C
Mycoses; 2020 Aug; 63(8):869-875. PubMed ID: 32406142
[TBL] [Abstract][Full Text] [Related]
36. Successful treatment of onychomycosis with ciclopirox nail lacquer: a case report.
Galitz J
Cutis; 2001 Aug; 68(2 Suppl):23-4. PubMed ID: 11665725
[TBL] [Abstract][Full Text] [Related]
37. Six novel antimycotics.
Rubin AI; Bagheri B; Scher RK
Am J Clin Dermatol; 2002; 3(2):71-81. PubMed ID: 11893219
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the antifungal efficacy of terbinafine hydrochloride and ciclopirox olamine containing formulations against the dermatophyte Trichophyton rubrum in an infected nail plate model.
Täuber A; Müller-Goymann CC
Mol Pharm; 2014 Jul; 11(7):1991-6. PubMed ID: 24490976
[TBL] [Abstract][Full Text] [Related]
39. Optimized Ciclopirox-Based Eudragit RLPO Nail Lacquer: Effect of Endopeptidase Enzyme as Permeation Enhancer on Transungual Drug Delivery and Efficiency Against Onychomycosis.
Khattab A; Shalaby S
AAPS PharmSciTech; 2018 Apr; 19(3):1048-1060. PubMed ID: 29138987
[TBL] [Abstract][Full Text] [Related]
40. Hydroxypropyl chitosan nail lacquer of ciclopirox-PLGA nanocapsules for augmented in vitro nail plate absorption and onychomycosis treatment.
Gaballah EY; Borg TM; Mohamed EA
Drug Deliv; 2022 Dec; 29(1):3304-3316. PubMed ID: 36372978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
